QNCX Earnings & Financial Statements
Quince Therapeutics, Inc.
$26.74
-$0.07(-0.26%)
24
Overall
40
Value
18
Tech
15
Quality
Market Cap
$27.27M
Volume
262
52W Range
$15.10 - $909.98
Target Price
$76.43
QNCX earnings and financial statements: Quince Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
QNCX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$58.07M | -$57.28M | -$34.62M | -$50.37M | -$90.32M |
| EBITDA | -$80.62M | -$56.55M | -$31.26M | -$50.37M | -$89.60M |
| Net income | -$83.98M | -$56.83M | -$31.39M | -$50.01M | -$89.94M |
| EPS (diluted) | $-1.68 | $-262.00 | $-168.00 | $-308.00 | $-606.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $93.52M | $114.48M | $167.90M | $103.91M | $133.23M |
| Total liabilities | $129.24M | $84.33M | $82.82M | $3.32M | $14.64M |
| Shareholders’ equity | -$35.71M | $30.15M | $85.08M | $100.59M | $118.59M |
| Cash and equivalents | $5.81M | $6.21M | $75.10M | $44.58M | $69.72M |
| Long-term debt | $330.0K | $14.71M | $13.75M | - | $420.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$41.42M | -$31.90M | -$18.29M | -$44.04M | -$62.93M |
| Capital expenditure | -$352.0K | -$257.0K | -$160.0K | -$133.0K | -$180.0K |
| Free cash flow | -$41.78M | -$32.16M | -$18.45M | -$44.17M | -$63.11M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | QNCX | $26.74 | -0.3% | 262 |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Quince Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW